A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients

Rudis, Maria I.; Sikora, Caryl Ann; Angus, Elizabeth M.; Peterson, Edward L.; Popovich, John; Hyzy, Robert C.; Zarowitz, Barbara J.

doi:10.1097/00003246-199704000-00005

Cited by 120 publications

(42 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies that have compared TOF-guided NMBA titration to titration based on subjective clinical assessments in patients with mixed indications for paralysis have yielded disparate results. Rudis et al 26 reported that lower doses of NMBAs were used and recovery from paralytic agents was faster in patients randomized to TOF-guided therapy, whereas 2 other studies 27,28 showed no difference between groups in total paralysis time, recovery time, and amount of drug used. In a randomized controlled trial 29 of 102 patients with ARDS who were given cisatracurium, Figure 4 Degree to which baseline factors or concurrent therapies are perceived to alter the risk profile of neuromuscular blocking agents.…”

Section: Discussionmentioning

confidence: 99%

Intensive Care Nurses' Knowledge About Use of Neuromuscular Blocking Agents in Patients With Respiratory Failure

Frazee¹,

Personett²,

Bauer³

et al. 2015

American Journal of Critical Care

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Intensive Care Nurses' Knowledge About Use of Neuromuscular Blocking Agents in Patients With Respiratory Failure

Frazee¹,

Personett²,

Bauer³

et al. 2015

American Journal of Critical Care

View full text Add to dashboard Cite

“…11,12,[21][22][23] Small, single-institution, prospective studies 1,22,23 suggest that the rates vary between 3.4% and 15.5%. Watling et al 17 reported a survey of the use of sedatives, analgesics, and NMB in the United States.…”

Section: Discussionmentioning

confidence: 99%

Use of Sedatives and Neuromuscular Blockers in a Cohort of Patients Receiving Mechanical Ventilation

Arroliga

Frutos‐Vivar

Hall

et al. 2005

Chest

184

View full text Add to dashboard Cite

Objective: To describe the use of sedatives and neuromuscular blocking agents (NMBs) and their impact in outcome in an international cohort of patients receiving mechanical ventilation. Methods: We analyzed the database of a prospective, multicenter cohort of 5,183 adult patients who received mechanical ventilation for > 12 h. We considered that a patient received a given agent when it was administered for at least 3 h in a 24-h period. Abbreviations: CI ϭ confidence interval; IQR ϭ interquartile range; NMB ϭ neuromuscular blocking agent; OR ϭ odds ratio; PEEP ϭ positive end-expiratory pressure; SAPS ϭ simplified acute physiology score S edatives, analgesics, and neuromuscular blocking agents (NMBs) are drugs commonly used in the ICU, mainly in patients requiring mechanical ventilation. 1 Sedatives and analgesics are often used to facilitate patient tolerance of invasive mechanical ventilation. The goals of sedation/analgesia in this context include decreasing pain and anxiety, reducing the stress response, and facilitating nursing care. 2,3 Studies 4 -7 have suggested that we need to pay attention to the way we provide sedation/analgesia because of the potential impact on patient outcomes such as length of stay in the ICU, days of mechanical ventilation, and rate of self-extubation.

show abstract

“…This search identified 38 articles and only English-language articles were reviewed to determine the original studies that evaluated pharmacist interventions on patient outcomes: four were clinical, ten economic, and zero humanistic. In addition to the clinical outcomes studies identified by our search, other relevant articles are discussed [3, 23,24]. This paper discusses the enhancement of outcomes by providing clinical pharmacy services to the critically ill in North America.…”

Section: Introductionmentioning

confidence: 99%

The impact of critical care pharmacists on enhancing patient outcomes

2003

View full text Add to dashboard Cite

The highly specialized knowledge and skills needed to care for critically ill patients requires a multidisciplinary team approach. Pharmacists are integral members of this team. They make valuable contributions to improve clinical, economic, and humanistic outcomes of patients. The purpose of this article is to review the literature pertaining to pharmacists' contributions within a multidisciplinary intensivist-led intensive care unit (ICU) team. Pharmacist interventions include correcting/clarifying orders, providing drug information, suggesting alternative therapies, identifying drug interactions, and therapeutic drug monitoring. Pharmacist involvement in improving clinical outcomes of critically ill patients is associated with optimal fluid management and substantial reductions in the rates of adverse drug events, medication administration errors, and ventilator-associated pneumonia. Furthermore, economic evaluations of clinical pharmacy services in the ICU consistently reveal the potential for considerable cost savings.

show abstract

A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients

Cited by 120 publications

References 43 publications

Intensive Care Nurses' Knowledge About Use of Neuromuscular Blocking Agents in Patients With Respiratory Failure

Intensive Care Nurses' Knowledge About Use of Neuromuscular Blocking Agents in Patients With Respiratory Failure

Use of Sedatives and Neuromuscular Blockers in a Cohort of Patients Receiving Mechanical Ventilation

The impact of critical care pharmacists on enhancing patient outcomes

Contact Info

Product

Resources

About